Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 Indication name: Post-traumatic stress disorder (PTSD)

Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Post-traumatic stress disorder (PTSD) is a complex mental disorder with psychological and emotional components, caused by exposure to single or repeated extreme traumatic events found in war, terrorist attacks, natural or man-caused disasters, and by violent personal assaults and accidents.

Epidemiology-

According to Thelansis, The lifetime prevalence of PTSD ranges from 5.7 to 8.8 percent in national samples of the general adult population in the United States, with one-year prevalence rates of 4.2 to 5.1 percent.

Competitive landscape of Post-traumatic stress disorder (PTSD) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Post-traumatic stress disorder (PTSD) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Post-traumatic stress disorder (PTSD) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 NYX-783 Aptinyx Phase 2
2 Nabiximols GW Pharmaceuticals Ltd. Phase 3
3 NBTX-001 Xenon Inhaler Nobilis Therapeutics Inc. Phase 3
4 BNC210 Bionomics Limited Phase 2
5 Brexpiprazole (OPC-34712) Otsuka Pharmaceutical Development & Commercialization, Inc. Phase 3
6 CBD Cannabis Tilray Phase 2
7 orvepitant GlaxoSmithKline Phase 2
8 BX-1 Bionorica SE Phase 2
9 Ganaxolone Marinus Pharmaceuticals Phase 2
10 Lu AG06466 H. Lundbeck A/S Phase 1
11 MDMA MAPS Europe B.V. Phase 2
12 Nepicastat Acorda Therapeutics Phase 2
13 TNX-102 SL 5.6 mg Tonix Pharmaceuticals, Inc. Phase 3

Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Respiratory syncytial virus (RSV)

Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Respiratory syncytial virus (RSV) is a filamentous enveloped, negative-sense, single-stranded RNA virus that belongs to the Orthopneumovirus genus of the Pneumoviridae family in the order Mononegavirales. This family also contains human metapneumovirus (hMPV), which belongs to the Metapneumovirus genus and, like RSV, is a major pathogen in children. The symptoms of RSV and hMPV infection are indistinguishable, and both are generally transmitted through close contact.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, and surveys estimated in the United States, nearly all children become infected with RSV by age 2, with 95,000 to 135,000 of them hospitalized each year. Approximately 0.5% to 2.0% of all children are hospitalized with lower respiratory tract disease, of which 50% to 90% face bronchiolitis and 5% to 40% encounter pneumonia. Globally, RSV affects an estimated 64 million people and causes 160,000 deaths each year.

Competitive landscape of Respiratory syncytial virus (RSV) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Respiratory syncytial virus (RSV) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Respiratory syncytial virus (RSV) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

 

Read more: Respiratory syncytial virus (RSV) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 GSK3844766A GlaxoSmithKline Phase 2
2 ALN-RSV01 Alnylam Pharmaceuticals Phase 2
3 EDP-938 Enanta Pharmaceuticals Phase 2
4 Presatovir Gilead Sciences Phase 2
5 PC786 Pulmocide Ltd Phase 2
6 MEDI8897 MedImmune LLC Phase 3
7 ALS-008176 Alios Biopharma Inc. Phase 1
8 MV-012-968 Meissa Vaccines, Inc. Phase 1
9 CodaVax-RSV Codagenix, Inc Phase 1
10 MVA-mBN294B Bavarian Nordic Phase 2
 

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Cushing’s Syndrome (CS)

Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

 

Cushing’s syndrome is a disorder that occurs when your body makes too much of the hormone cortisol over a long period of time. Cushing’s syndrome can be caused by overuse of cortisol medication, as seen in the treatment of chronic asthma or rheumatoid arthritis (iatrogenic Cushing’s syndrome), excess production of cortisol from a tumor in the adrenal gland or elsewhere in the body (ectopic Cushing’s syndrome) or a tumor of the pituitary gland secreting adrenocorticotropic hormone (ACTH) which stimulates the over-production of cortisol from the adrenal gland (Cushing’s disease).

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, pituitary ACTH-dependent Cushing's causes 68% to 72% of Cushing's syndrome. The reported incidence was 1.53 to 2.43 per million per year in European population-based studies and 6.3 to 7.3 per million person-years in the United States

Competitive landscape of Cushing’s Syndrome (CS) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cushing’s Syndrome (CS) 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cushing’s Syndrome (CS) market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

 

Read more: Cushing’s Syndrome (CS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Partner Phase
1 Korlym Corcept Therapeutics Inc. N/A Approved
2 Signifor Recordati SpA Novartis Approved
3 Ketoconazole HRA Pharma N/A Approved in Europe
4 Cytadren Novartis AG N/A Withdrawn from Market
5 Osilodrostat Recordati SpA Novartis NDA
6 Recorlev Strongbridge Biopharma plc N/A III
7 Relacorilant Corcept Therapeutics Inc. N/A III
8 Mifedren HRA Pharma N/A II/III
9 Nevanimibe Millendo Therapeutics, Inc. N/A II
10 Lysodren HRA Pharma N/A Investigator Initiated
11 Seliciclib Cyclacel Pharmaceuticals, Inc. ManRos Therapeutics Investigator Initiated
12 COR-005 Strongbridge Biopharma plc Evotec Development Outside U.S.
13 HTL0030310 Sosei Co., Ltd N/A Development Outside U.S.
14 ACTH Antagonist (Crinetics) Crinetics Pharmaceuticals, Inc. N/A Preclinical
15 Anti-ACTH XOMA Corporation N/A Preclinical
16 AP102 Amryt Pharma plc N/A Preclinical
17 BIM23B065 Ipsen SA N/A Preclinical
18 Steroidogenic factor-1 (SF-1) Antagonists Orphagen Pharmaceuticals N/A Preclinical

Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Acromegaly

Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Acromegaly is a disorder that occurs when your body makes too much growth hormone (GH). Produced mainly in the pituitary gland, GH controls the physical growth of the body. Acromegaly may also cause thickening of the soft tissues of the body, including the heart, lips, and tongue. When the disease affects children prior to the end of puberty, excess growth hormone can lead to accelerated growth and tall stature, known as gigantism. Acromegaly may be caused by the ineffective control of growth hormone-secreting cells by the hypothalamus (a gland in the brain that regulates hormone secretions).

In rare cases, non-pituitary tumors in the pancreas, lungs or adrenal glands may cause acromegaly. In some cases, acromegaly may occur as part of certain genetic syndromes including multiple endocrine neoplasia type 1, familial isolated pituitary adenoma, the Carney complex and McCune-Albright syndrome. X-linked acrogigantism causes gigantism and is due to microduplications of segments of the X chromosome.

Epidemiology-
About 3 to 14 of every 100,000 people have been diagnosed as having acromegaly.

Competitive landscape of Acromegaly includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Acromegaly 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Acromegaly market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Acromegaly – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No Asset Company Stage
1 Sandostatin Novartis AG Approved (Generic Competition)
2 Sandostatin LAR Novartis AG Approved
3 Signifor Recordati SpA Approved
4 Somatuline Autogel Ipsen SA Approved
5 Somavert Nektar Therapeutics Approved
6 CAM2029 Novartis AG III
7 Mycapssa Chiasma, Inc III
8 ATL1103 Antisense Therapeutics, Ltd. II
9 COR-005 Strongbridge Biopharma plc II
10 CRN00808 Crinetics Pharmaceuticals, Inc. II
11 IONIS-GHR-LRx Ionis Pharmaceuticals, Inc. II
12 DP1038 Dauntless Pharmaceuticals, Inc. I
13 Glide Octreotide Enesi Pharma Limited I
14 ONO-5788 Ono Pharmaceutical Company, Ltd. I
15 Q-Octreotide Midatech Pharma PLC I
16 ITF-2984 Italfarmaco S.p.A. Development Outside U.S.
17 AP102 Amryt Pharma plc Preclinical
18 AQST-305 Aquestive Therapeutics, Inc Preclinical 

Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Mesothelioma

Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Mesothelioma is a type of cancer that develops in the lining that covers the outer surface of some of the body's organs. It's usually linked to asbestos exposure. Mesothelioma mainly affects the lining of the lungs (pleural mesothelioma), although it can also affect the lining of the tummy (peritoneal mesothelioma), heart, or testicles.

The four types of mesothelioma are identified by the location in the body where tumors develop. Pleural and peritoneal types of mesothelioma are the most common. Pericardial and testicular mesothelioma accounts for less than 2% of cases combined.

Epidemiology-

According to Thelansis disease modeling data and literature review estimated approximately 3350 cases of malignant mesothelioma are diagnosed annually. In the absence of occupational exposure to asbestos, the incidence is 0.1-0.25 per 100,000 population in both sexes. The risk of mesothelioma is increased in polluted areas by 2-10 fold compared with non-polluted areas. In patients with malignant mesothelioma in the United States, 80% have been exposed to asbestos.

Competitive landscape of Mesothelioma includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Mesothelioma 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.
Mesothelioma market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Mesothelioma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 ONCOFID®-P Fida Farmaceutici Phase 2
2 MTG201 Momotaro-Gene Inc. Phase 2
3 MesoPher Amphera BV Phase 3
4 YS110 Kissei Pharmaceutical Co., Ltd. Phase 2
5 IAG933 Novartis Pharmaceuticals Phase 1
6 Expansion Cohort Oncovir, Inc. Phase 1
7 BBI608 Sumitomo Dainippon Pharma Co., Ltd. Phase 2
8 Pembrolizumab Merck Sharp & Dohme Corp. Phase 1
9 BAY2287411 Bayer Phase 1
10 Nivolumab Injection Bristol-Myers Squibb Phase 3
11 rAd-IFN Trizell Ltd Phase 3
12 Pemetrexed NovoCure Ltd. Phase 2
13 Immunotherapy plus chemotherapy Aduro Biotech, Inc. Phase 1
14 HMPL-453 Hutchison Medipharma Limited Phase 2
15 ONCOS-102 Theradex Phase 2
16 WT-1-vaccine Montanide + GM-CSF Sellas Life Sciences Group Phase 2
17 ADI-PEG 20 plus Pem Cis Polaris Group Phase 3
18 Vorinostat Merck Sharp & Dohme Corp. Phase 3
19 Tazemetostat Epizyme, Inc. Phase 2
20 NGR-hTNF plus Best Investigator's Choice (BIC) AGC Biologics S.p.A. Phase 3
21 Tremelimumab MedImmune LLC Phase 2
22 Avelumab Pfizer Phase 2
23 pemetrexed, cisplatin and CBP501 CanBas Co. Ltd. Phase 2
24 SAR444245 Sanofi Phase 2
25 Vinorelbine Pierre Fabre Laboratories Phase 2
26 Durvalumab PrECOG, LLC. Phase 2
27 Trabectedin PharmaMar Phase 2
28 Bevacizumab and Atezolizumab Hoffmann-La Roche Phase 3
29 cyclophosphamide Atara Biotherapeutics Phase 1
30 Alisertib Millennium Pharmaceuticals, Inc. Phase 2
31 MCY-M11 MaxCyte, Inc. Phase 1
32 VT3989 Vivace Therapeutics, Inc Phase 1
33 αPD1-MSLN-CAR T cells Shanghai Cell Therapy Group Co.,Ltd Phase 1
34 GL-ONC1 Genelux Corporation Phase 1
35 APG-2449 Ascentage Pharma Group Inc. Phase 1
36 S-488210 Shionogi Inc. Phase 1
37 SG001 CSPC ZhongQi Pharmaceutical Technology Co., Ltd. Phase 1
38 SCH 721015 Biogen Phase 1
39 SGN-CD228A Seagen Inc. Phase 1
40 INCB001158 Incyte Corporation Phase 2
41 AdV-tk + valacyclovir Candel Therapeutics, Inc. Phase 1
42 gavo-cel TCR2 Therapeutics Phase 2
43 NGM707 NGM Biopharmaceuticals, Inc Phase 2
44 INBRX-109 Inhibrx, Inc. Phase 1
45 VMD-928 VM Oncology, LLC Phase 1
46 CB-839 Calithera Biosciences, Inc Phase 1
47 SO-C101 Sotio a.s. Phase 1
48 QBS10072S Quadriga Biosciences, Inc. Phase 1
49 IOA-244 iOnctura Phase 1
50 ASTX295 Astex Pharmaceuticals, Inc. Phase 2 

Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Cystic fibrosis

Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Cystic fibrosis is an autosomal recessive disease caused by mutations in the gene for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. CFTR is an ion channel protein that transports chloride ions across the membranes of cells that line airways, glands, and the digestive tract.

Epidemiology-

According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses, the prevalence of Cystic fibrosis in a range of 0.72 to 0.76 per 10,000 in the 27 EU countries, whereas prevalence is reported to be 0.81 in the United States.

Competitive landscape of Cystic fibrosis includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Cystic fibrosis 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Cystic fibrosis market forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Cystic fibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 VX-121 & VX-561 Vertex Pharmaceuticals Incorporated Phase 3
2 Galicaftor AbbVie Phase 2
3 P-1037 Parion Sciences Phase 2
4 MP-376 Horizon Pharma USA, Inc. Phase 3
5 AIR DNase Protalix Phase 1
6 Ultrase® MT20 Forest Laboratories Phase 3
7 Cavosonstat Nivalis Therapeutics, Inc. Phase 2
8 BI 443651 Boehringer Ingelheim Phase 1
9 ALX-009 Alaxia SAS Phase 1
10 POL6014 Santhera Pharmaceuticals Phase 2
11 Cavosonstat Nivalis Therapeutics, Inc. Phase 2
12 ELX/TEZ/IVA Vertex Pharmaceuticals Incorporated Phase 3
13 Ataluren (PTC124®) PTC Therapeutics Phase 3
14 Liposomal amikacin for inhalation Insmed Incorporated Phase 3
15 OligoG DPI AlgiPharma AS Phase 2
16 QR-010 ProQR Therapeutics Phase 1
17 CHF 6333 Chiesi Farmaceutici S.p.A. Phase 1
18 Cysteamine NovaBiotics Ltd. Phase 2
19 AZLI Gilead Sciences Phase 3
20 Vancomycin inhalation powder Savara Inc. Phase 3
21 TOBI Novartis Pharmaceuticals Phase 3
22 AZLI Gilead Sciences Phase 3
23 MRT5005 Translate Bio, Inc. Phase 2
24 MS1819-SD AzurRx SAS Phase 2
25 SPI-1005 Sound Pharmaceuticals, Incorporated Phase 2
26 N91115 Nivalis Therapeutics, Inc. Phase 1
27 Nitric oxide Beyond Air Inc. Phase 2
28 QR-010 ProQR Therapeutics Phase 2
29 AIR DNase™ Protalix Phase 2
30 EUR-1008 (APT-1008) Forest Laboratories Phase 3 
 

Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Indication name: Fibromyalgia

Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Fibromyalgia is a syndrome characterized by chronic widespread pain at multiple tender points, joint stiffness, and systemic symptoms (e.g., mood disorders, fatigue, cognitive dysfunction, and insomnia) [1–4] without a well-defined underlying organic disease.

Fibromyalgia classification based on the triggers:

Cervical pathology.
Metabolic/endocrine conditions.
Inflammatory/autoimmune conditions.
Peripheral/central nervous system conditions.
Mixed

Epidemiology-

According to systematic literature survey and Thelansis disease modeling data Fibromyalgia disorder affects an estimated 10 million people in the U.S. and an estimated 3-6% of the world population. While it is most prevalent in women. 75-90 percent of the people who have FM are women.

Competitive landscape of Fibromyalgia includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Fibromyalgia across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Fibromyalgia Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Fibromyalgia – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

S. No Asset Company Stage
1 NYX-2925 Aptinyx Phase 2
2 ASP0819 Astellas Pharma Inc Phase 2
3 TD-9855 Group 1 Theravance Biopharma Phase 2
4 TNX-102 SL Tonix Pharmaceuticals, Inc. Phase 3
5 INC-1 Virios Therapeutics, Inc. Phase 2
6 Duloxetine Eli Lilly and Company Phase 3
7 [S,S]-Reboxetine Pfizer Phase 3
8 Fremanezumab - Dose A Teva Branded Pharmaceutical Phase 2
9 Device: AVACEN Thermal Exchange System Avacen, Inc. Phase 2
10 DS-5565 Syneos Health Phase 3
11 DS-5565 Daiichi Sankyo, Inc. Phase 3
12 Pregabalin Release Tablets Jiangsu HengRui Medicine Co., Ltd. Phase 3
13 GRT9906 Grünenthal GmbH Phase 2
14 ropinirole GlaxoSmithKline Phase 2
15 Lacosamide UCB Pharma Phase 2
16 KL16-012 Knop Laboratorios Phase 2
17 Injectafer American Regent, Inc. Phase 2
18 Botulinum toxin type A Ipsen Phase 2
19 Botulinum toxin type A Allergan Phase 3
20 Ibuprofen Spherium Biomed Phase 2
21 Erenumab-aooe (EREN) Novartis Pharmaceuticals Phase 2

Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Stargardt Disease

Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Stargardt disease is also called Stargardt macular dystrophy, juvenile macular degeneration, or fundus flavimaculatus. The disease causes progressive damage — or degeneration — of the macula, which is a small area in the center of the retina that is responsible for sharp, straight-ahead vision. In most cases, Stargardt macular degeneration is caused by mutations in the ABCA4 gene. Less often, mutations in the ELOVL4 gene cause this condition. The ABCA4 and ELOVL4 genes provide instructions for making proteins that are found in light-sensing (photoreceptor) cells in the retina.

Classification-

Fishman STGD Classification

Stage 1:

Pigmentary changes in the macula or pisciform ring of flecks within 1 DD on all sides of the fovea.

           ERG and EOG are normal

      Stage 2:

            Pisciform flecks present beyond 1 DD of the fovea, often extending beyond the arcades and nasal to the optic disc

            ERG and EOG normal, but cone/rod response may be subnormal

     Stage 3:

           Diffusely resorbed flecks and choriocapillaris atrophy of the macula

           EOG subnormal

           ERG subnormal cone or rod amplitudes

          Central field defects + midperipheral/peripheral field defect

    Stage 4:

          Diffusely absorbed flecks and choriocapillaris/RPE  atrophy throughout the entire fundus

          ERG with reduced rod and cone amplitudes

          Peripheral fields with moderate to extensive restriction

Epidemiology- Stargardt macular degeneration is the most common form of juvenile macular degeneration, the signs and symptoms of which begin in childhood. A prospective epidemiologic study (Cornish et. al 2017) undertaken under the auspices of the British Ophthalmological Surveillance Unit (BOSU) suggests an annual incidence in the United Kingdom of between 0.110 and 0.128 per 100 000 individuals. Thelansis estimated prevalence of Stargardt macular degeneration is 1 in 8,000 to 10,000 individuals.

Competitive landscape of Stargardt Disease includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Stargardt Disease across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Stargardt Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Stargardt Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Phase

1        ACU-4429        Kubota Pharmaceutical Holdings Co., Ltd.        N/A        III

2        Zimura        Iveric Bio        Archemix        IIb

3        ALK-001        Alkeus Pharmaceuticals, Inc.        N/A        II

4        ASP7317        Astellas Pharma, Inc.        CHA Bio & Diostech        II

5        LBS-008        Lin Bioscience, Inc.        N/A        I

6        NSR-ABCA4        Biogen, Inc.        N/A        Preclinical

7        QRX-1011        ProQR Therapeutics N.V.        N/A        Preclinical

8        REV-0100        reVision Therapeutics, Inc.        Cornell University        Preclinical

9        Stargardt Program        Applied Genetic Technologies Corporation        N/A        Preclinical

10        STGD1 Minigene Program (IVERIC/UMass)        Iveric Bio        N/A        Preclinical

Fragile X syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Fragile X syndrome

Fragile X syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Usually, males are more severely affected by this disorder than females. FXS is caused by the transcriptional silencing of the FMR1 gene (Xq27.3) due to the progressive expansion and subsequent methylation of (CGG)n trinuleotide repeats in the 5'-untranslated region of the gene. These full mutations originate from unstable alleles called premutations (55-200 CGG repeats). In some rare cases, FXS was shown to result from intragenic FMR1 point mutations or deletions. FMR1 codes for the FMRP, an RNA-binding protein that regulates protein synthesis and other signaling pathways in neuronal dendrites. FMR1 silencing is thought to reduce synaptic plasticity and modulation throughout the brain including the hippocampus.

The Three Fragile X-Associated Disorders

Fragile X Syndrome

Fragile X-Associated Tremor/Ataxia Syndrome

Fragile X-Associated Primary Ovarian Insufficiency

Epidemiology- Thelansis estimates, fragile X syndrome affects about 1 in 4,000 males and 1 in 6,000 to 8,000 females in the USA; that is, it affects about twice as many males as it does females. However, about four times as many females appear to be carriers of the altered gene as do males (1:250 females and 1:1000 males).

Competitive landscape of Fragile X syndrome includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Fragile X syndrome across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Fragile X syndromeMarket Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Fragile X syndrome – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company         Partner        Phase

1        Zygel        Zynerba Pharmaceuticals, Inc.        N/A        III

2        BPN14770        Tetra Therapeutics        Shionogi        II

3        Ganaxolone        Marinus Pharmaceuticals, Inc.        Ligand        II

4        OV101        Ovid Therapeutics, Inc.        Lundbeck        II

5        AUT00206        Autifony Therapeutics Limited        Boehringer Ingelheim        I

6        Abilify (Oral and IM)        Otsuka Holdings Co., Ltd.        Ligand; Lundbeck        Investigator Initiated

7        Campral        Merck KGaA        Allergan        Investigator Initiated

8        Zoloft        Pfizer Inc.        N/A        Investigator Initiated

9        MDX        Arcturus Therapeutics Ltd.        N/A        Development Outside U.S.

10        Acamprosate        Aclaris Therapeutics, Inc.        AOP Orphan Pharmaceuticals        Preclinical

11        ANAVEX 2-73        Anavex Life Sciences Corp.        N/A        Preclinical

12        Bryostatin        Neurotrope, Inc.        N/A        Preclinical

13        DgkK Gene Therapy Program (Lysogene)        Lysogene SA        N/A        Preclinical

14        GWP42006        GW Pharmaceuticals plc        Otsuka        Preclinical

15        NNZ-2591        Neuren Pharmaceuticals Limited        N/A        Preclinical

16        p70S6K Inhibitor (Epigen)        Epigen Biosciences, Inc.        N/A        Preclinical

17        PAK Inhibitor        Roche Holding AG        Afraxis        Preclinical

18        SOL101        Sentinel Oncology Limited        N/A        Preclinical

Hunter syndrome (Mucopolysaccharidosis Type II) – Market Access, Reimbursement, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Hunter syndrome (Mucopolysaccharidosis Type II)

Hunter syndrome (Mucopolysaccharidosis Type II) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Hunter syndrome, also known as Mucopolysaccharidosis II is a rare X-linked recessive disorder caused by deficiency of the lysosomal enzyme iduronate sulfatase, leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues, and organs. Mutations in the IDS gene cause MPS II. The IDS gene provides instructions for producing the I2S enzyme, which is involved in the breakdown of large sugar molecules called glycosaminoglycans (GAGs).

Two relatively distinct clinical forms of MPS II have been recognized i.e., the non-neuronopathic form (formerly defined as slowly progressive milder form) of the disease, intelligence may be normal or only slightly impaired and neuronopathic form of the disease (formerly called early progressive more severe form), intellectual disabilities may be apparent in the early life of the patient.

Epidemiology- Thelansis estimates MPS II typically affects only males, with symptoms becoming apparent at approximately 2-4 years of age. The disorder occurs in approximately 1 in 100,000 to 1 in 170,000 male births.

Competitive landscape of Hunter syndrome (Mucopolysaccharidosis Type II) includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Hunter syndrome (Mucopolysaccharidosis Type II) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Hunter syndrome (Mucopolysaccharidosis Type II) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Hunter syndrome (Mucopolysaccharidosis Type II) – Market Access, Reimbursement, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Asset        Company        Stage

iduronate-2-sulfatase, Green Cross        GC Pharma        Launched

idursulfase        Takeda        Launched

JR-141        JCR Pharmaceuticals        Phase III

AGT-182        ArmaGen        Phase II

idursulfase-beta (sc), Green Cross        GC Pharma        Phase II

RGX-121        REGENXBIO        Phase II

SB-913        Sangamo Therapeutics        Phase II

odiparcil, Inventiva        Inventiva        Phase II

DNL-310        Denali Therapeutics        Pre-clinical

EGT-301        Esteve        Pre-clinical

Mucopolysaccharidosis type II therapy, Immusoft        Immusoft        Pre-clinical

 

Huntington Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

Indication name: Huntington Disease

Huntington’s Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Huntington disease (HD) is a brain disease that is passed down in families from generation to generation. HD causes deterioration in a person’s physical, mental, and emotional abilities, usually during their prime working years, and currently has no cure. Most people start developing symptoms during adulthood, between the ages of 30 to 50, but HD can also occur in children and young adults (known as juvenile HD or JHD). HD is known as a family disease because every child of a parent with HD has a 50/50 chance of inheriting the faulty gene. Huntington disease (HD) is caused by a change (mutation) in the HTT gene. This gene gives instructions for making a protein called huntingtin. The HTT gene mutation that causes HD involves a DNA segment known as a CAG trinucleotide repeat.

Types of Huntington's Disease

Huntington's disease has two subtypes:

Adult-onset Huntington's disease- This is the most common form of Huntington's disease. People with adult-onset Huntington's disease usually develop symptoms in their mid-40s and 50s.

Juvenile Huntington's disease- Children and teenagers have this form of Huntington's disease, which is very rare. Children with Huntington's disease often have symptoms similar to Parkinson's disease. They may also develop problems with schoolwork.

Epidemiology- according to Thelansis about 42,000 people in the United States have Huntington’s disease and another 220,000 are at risk of developing the condition.

Competitive landscape of Huntington Disease includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Huntington Disease across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Huntington Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Huntington Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No        Asset        Company        Partner        Phase

1        Xenazine        Bausch Health Companies Inc.        Lundbeck        Approved (Generic Competition)

2        Austedo        Teva Pharmaceutical Industries Ltd.        N/A        Approved

3        Ingrezza        Neurocrine Biosciences, Inc.        Mitsubishi Tanabe Pharma        III

4        Tominersen        Roche Holding AG        Ionis Pharmaceuticals        III

5        Neflamapimod        EIP Pharma, Inc.        Vertex Pharmaceuticals        II

6        Pepinemab        Vaccinex, Inc.        N/A        II

7        SEN196        AOP Orphan Pharmaceuticals AG        Elixir Pharmaceuticals; Siena Biotech        II

8        TV-7820        Prilenia Therapeutics Development Ltd.        NeuroSearch        II

9        AMT-130        uniQure N.V.        N/A        I/II

10        SRX246        Azevan Pharmaceuticals        N/A        I/II

11        WVE-120101        WAVE Life Sciences Ltd.        Takeda Pharmaceutical        I/II

12        WVE-120102        WAVE Life Sciences Ltd.        Takeda Pharmaceutical        I/II

13        NP03        Medesis Pharma SA        N/A        I

14        SAGE-718        Sage Therapeutics, Inc.        N/A        I

15        T3D-959        T3D Therapeutics, Inc.        Bayer; Midatech        I

16        ANX-005        Annexon, Inc.        N/A        IND

17        Cannabinoid Program (Scythian)        SOL Global Investments Corp.        N/A        IND

18        Dojolvi        Ultragenyx Pharmaceutical Inc.        Baylor Research Institute; Uniquest        Investigator Initiated

19        GSK-2245840        GlaxoSmithKline plc        N/A        Investigator Initiated

20        SBT-20        Stealth BioTherapeutics Inc.        N/A        Status to confirm

21        SOM3355        SOM Biotech        Nippon Chemiphar        Status to confirm

22        AON Program (Vico)        Vico Therapeutics        N/A        Preclinical

23        BCR159        BioCrea GmbH        N/A        Preclinical

24        BV-CYP01        BrainVectis        N/A        Preclinical

25        EHP-102        Emerald Health Pharmaceuticals Inc.        N/A        Preclinical

26        HTT Program (Exicure)        Exicure, Inc.        N/A        Preclinical

27        Huntington's Disease Program (CHDI/Evotec)        Evotec SE        CHDI Foundation        Preclinical

28        INT41        Vybion Inc.        N/A        Preclinical

29        mAB C6-17        AFFiRiS GmbH        N/A        Preclinical

30        MMJ-002        MMJ Group Holdings Ltd        N/A        Preclinical

31        MP101        Mitochon Pharmaceuticals, Inc.        N/A        Preclinical

32        NLS-12        NLS Pharmaceutics AG        N/A        Preclinical

33        NT0100        NeuBase Therapeutics, Inc.        N/A        Preclinical

34        NurOwn        BrainStorm Cell Therapeutics Inc.        N/A        Preclinical

35        ReN001        ReNeuron Group plc        Fosun Pharma        Preclinical

36        RT001 (Retrotope)        Retrotope, Inc.        N/A        Preclinical

37        S107        ARMGO Pharma, Inc.        N/A        Preclinical

38        Small Molecule Program (PTC/CHDI Foundation)        PTC Therapeutics, Inc.        CHDI Foundation        Preclinical

39        TTX-3360        Triplet Therapeutics, Inc.        N/A        Preclinical

40        VY-HTT01        Voyager Therapeutics, Inc        Sanofi; CHDI Foundation        Preclinical

41        WVE-003        WAVE Life Sciences Ltd.        Takeda Pharmaceutical        Preclinical

42        ZFP TF - Huntingtin Repressor        Sangamo Therapeutics, Inc.        Takeda Pharmaceutical        Preclinical

Narcolepsy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

Indication name: Narcolepsy

"Narcolepsy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China).

Narcolepsy is a sleep disorder characterized by excessive sleepiness, sleep paralysis, hallucinations, and in some cases episodes of cataplexy (partial or total loss of muscle control, often triggered by a strong emotion such as laughter). Narcolepsy type 1 occurs when nearly all of the neurons that contain orexin (also called hypocretin) are lost.  The reason for this is not fully understood, but it is thought to be an autoimmune process possibly triggered by an infection. HLA haplotype DQB1*0602 is present in 95% of narcolepsy type 1 patients, but this is also present in about 20% of the general population without narcolepsy. The cause of narcolepsy type 2 is not entirely clear. Current hypotheses include less destruction of orexin cells, impaired orexin receptor signaling, or an unknown mechanism.

Narcolepsy classified into two types;

Narcolepsy Type 1 – This type of narcolepsy involves a combination of excessive daytime sleepiness and one or both of the following:

Cataplexy is when you have attacks that cause a sudden loss of muscle tone while you are awake. It may lead to slurred speech and buckling knees, or in more severe cases complete paralysis. These events are usually triggered by strong emotions such as joy, surprise, laughter or anger.

Low or absent CSF hypocretin-1 levels. Narcolepsy type 1 is caused by a deficiency of hypocretin (orexin). A patient with low hypocretin has narcolepsy type 1, even if they don’t exhibit cataplexy.

Narcolepsy Type 2 – This type of narcolepsy occurs when you have continuous excessive sleepiness but no cataplexy. You may take a nap for a couple of hours and wake up feeling refreshed. But after a short time, you feel tired again.

Epidemiology- according to Thelansis Narcolepsy prevalence is 14 per 100,000 people for narcolepsy type 1 and 65.4 per 100,000 people for narcolepsy type 2. Incidence is highest in the late teens to early twenties with a 50% greater female predominance in the U.S

Competitive landscape of Narcolepsy includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Narcolepsy across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Narcolepsy Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Narcolepsy – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

S. No     Asset     Company              Partner            Phase

1            Dexedrine          Amneal Pharmaceuticals, Inc.     GlaxoSmithKline              Approved (Generic Competition)

2            Nuvigil  Teva Pharmaceutical Industries Ltd.        N/A       Approved (Generic Competition)

3            Provigil (Sparlon)            Teva Pharmaceutical Industries Ltd.              Takeda Pharmaceutical Approved (Generic Competition)

4            Sunosi  Jazz Pharmaceuticals plc              SK Biopharmaceuticals; Shionogi; Aerial BioPharma         Approved

5            Wakix   Harmony Biosciences Holdings, Inc.         Bioprojet; Ferrer; Endo International         Approved

6            Xyrem   Jazz Pharmaceuticals plc              UCB; Bausch Health              Approved

7            Xywav   Jazz Pharmaceuticals plc              N/A       Approved

8            FT218    Avadel Pharmaceuticals plc         N/A       III

9            Quilience            NLS Pharmaceutics AG   Adare   III

10          AXS-12  Axsome Therapeutics, Inc.          Pfizer    II

11          BTD-001             Balance Therapeutics, Inc.           N/A       II

12          SUVN-G3031      Suven Life Sciences Ltd. N/A       II

13          THN102              TheraNexus       N/A       II

14          TAK-925              Takeda Pharmaceutical Co. Ltd. N/A       I

15          TAK-994              Takeda Pharmaceutical Co. Ltd. N/A       I

16          XWL-008             XWPharma        N/A       I

17          XW10172            XWPharma        N/A       Status to confirm

18          EVT 501              Evotec SE            N/A       Preclinical

19          SLS-010 Seelos Therapeutics, Inc.             Ligand   Preclinical